KR100996378B1 - 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물 - Google Patents

선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물 Download PDF

Info

Publication number
KR100996378B1
KR100996378B1 KR1020097024731A KR20097024731A KR100996378B1 KR 100996378 B1 KR100996378 B1 KR 100996378B1 KR 1020097024731 A KR1020097024731 A KR 1020097024731A KR 20097024731 A KR20097024731 A KR 20097024731A KR 100996378 B1 KR100996378 B1 KR 100996378B1
Authority
KR
South Korea
Prior art keywords
pyridinylmethyl
bis
benzenedimethanamine
tetrahydro
methylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020097024731A
Other languages
English (en)
Korean (ko)
Other versions
KR20090130152A (ko
Inventor
개리 제이 브릿저
마이클 제이 아브람스
게오프레이 더블유 헨슨
로날드 트레버 맥파랜드
개리 비 칼란드라
데이비드 씨 데일
할 이 브록스마이어
Original Assignee
아노르메드 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100996378(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아노르메드 인코포레이티드 filed Critical 아노르메드 인코포레이티드
Publication of KR20090130152A publication Critical patent/KR20090130152A/ko
Application granted granted Critical
Publication of KR100996378B1 publication Critical patent/KR100996378B1/ko
Assigned to 겐자임 글로벌 에스에이알엘 reassignment 겐자임 글로벌 에스에이알엘 권리의 전부이전등록 Assignors: 아노메드 코포레이션
Assigned to 아노메드 코포레이션 reassignment 아노메드 코포레이션 권리의 전부이전등록 Assignors: 아노르메드 인코포레이티드
Assigned to 젠자임 코포레이션, 겐자임 쎄라퓨틱 프로덕츠 리미티드 파트너쉽 reassignment 젠자임 코포레이션 권리의 전부이전등록 Assignors: 겐자임 글로벌 에스에이알엘
Assigned to 젠자임 코포레이션 reassignment 젠자임 코포레이션 권리의 전부이전등록 Assignors: 겐자임 쎄라퓨틱 프로덕츠 리미티드 파트너쉽
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020097024731A 2001-07-31 2002-07-30 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물 Expired - Lifetime KR100996378B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US60/309,196 2001-07-31
US38215502P 2002-05-20 2002-05-20
US60/382,155 2002-05-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7001333A Division KR20040020075A (ko) 2001-07-31 2002-07-30 선조/줄기 세포를 가동시키는 방법

Publications (2)

Publication Number Publication Date
KR20090130152A KR20090130152A (ko) 2009-12-17
KR100996378B1 true KR100996378B1 (ko) 2010-11-25

Family

ID=26976666

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097024731A Expired - Lifetime KR100996378B1 (ko) 2001-07-31 2002-07-30 선조/줄기 세포를 이동시킴으로써 이식에 사용하기 위한 약제학적 조성물
KR10-2004-7001333A Ceased KR20040020075A (ko) 2001-07-31 2002-07-30 선조/줄기 세포를 가동시키는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2004-7001333A Ceased KR20040020075A (ko) 2001-07-31 2002-07-30 선조/줄기 세포를 가동시키는 방법

Country Status (28)

Country Link
US (9) US6987102B2 (enExample)
EP (3) EP2371361B1 (enExample)
JP (2) JP5137288B2 (enExample)
KR (2) KR100996378B1 (enExample)
CN (2) CN102302493B (enExample)
AT (1) ATE538785T1 (enExample)
AU (1) AU2002318927B2 (enExample)
BE (1) BE2019C544I2 (enExample)
BR (1) BRPI0211570B8 (enExample)
CA (1) CA2455559C (enExample)
CY (4) CY1112633T1 (enExample)
DK (2) DK2371361T3 (enExample)
ES (2) ES2742730T3 (enExample)
FR (2) FR12C0042I1 (enExample)
HU (1) HUP0402360A2 (enExample)
IL (2) IL159312A0 (enExample)
LT (2) LT2371361T (enExample)
LU (2) LU92033I2 (enExample)
MX (1) MXPA04000982A (enExample)
NL (2) NL300537I2 (enExample)
NO (4) NO336989B1 (enExample)
NZ (1) NZ530169A (enExample)
PL (1) PL364673A1 (enExample)
PT (2) PT2371361T (enExample)
RU (1) RU2309741C2 (enExample)
SI (2) SI2371361T1 (enExample)
WO (1) WO2003011277A2 (enExample)
ZA (1) ZA200400658B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
JP5137288B2 (ja) * 2001-07-31 2013-02-06 アノーメッド インコーポレイティド 前駆／幹細胞を動員する方法
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN1596255A (zh) 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
JP4667241B2 (ja) * 2003-06-27 2011-04-06 旭化成株式会社 細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
JP2007535479A (ja) 2003-08-13 2007-12-06 チルドレンズ ホスピタル メディカル センター ＧＴＰａｓｅを調節するためのキメラペプチド
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
EP1796716A4 (en) * 2004-08-13 2010-09-08 Anormed Inc COMBINATIONS OF CHEMOKINES FOR MOBILIZING PROGENITOR / STEM CELLS
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
US9789171B2 (en) * 2004-11-05 2017-10-17 The General Hospital Corporation Anti-fugetactic agents for the treatment of ovarian cancer
AU2006259630B2 (en) 2005-06-13 2011-10-27 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
CA2619828A1 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2007025166A2 (en) * 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
AU2006340074A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
WO2007108689A2 (en) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Method for induction of differentiation of stem and progenitor cells
MX2009001445A (es) * 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20110245265A1 (en) * 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
US20130039882A1 (en) * 2009-10-28 2013-02-14 Henry Ford Health System Method to mitigate injury from radiation exposure
CN101716167B (zh) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20150030561A1 (en) 2011-05-16 2015-01-29 Genzyme Corp. Use of CXCR4 Antagonists
EP2968563A4 (en) * 2013-03-15 2016-11-30 Leonard B Miller COMBINED TREATMENT TO IMPROVE MOU TISSUE HEALING, HEALING ADIPOSE TISSUE GRAFT, ENDOCHREST BONE SEWAGE AND OSTEOINTEGRATION
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
HK1259026A1 (zh) 2015-09-18 2019-11-22 综合医院公司以麻省总医院名义经营 用於治疗癌症的抗趋除剂的局部递送
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017216373A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
US11453706B2 (en) 2016-09-09 2022-09-27 The General Hospital Corporation HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
EP3509609A4 (en) 2016-09-09 2021-01-20 The General Hospital Corporation HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLENT FOR THE TREATMENT OF CANCER
WO2018049120A1 (en) 2016-09-09 2018-03-15 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10709763B2 (en) * 2017-12-19 2020-07-14 Gpcr Therapeutics, Inc. GPCR heteromer inhibitors and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12059437B2 (en) 2019-10-08 2024-08-13 The Regents Of The University Of California Methods and compositions for hematopoietic stem cell mobilization
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
JP2024536246A (ja) 2021-10-01 2024-10-04 ヤンセン ファーマシューティカ エヌ．ベー． 前駆細胞産生を増加させる方法
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors
CN118987175A (zh) * 2024-08-13 2024-11-22 广东壹加再生医学研究院有限公司 普乐沙褔联合粒细胞集落刺激因子在制备治疗脑梗死的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028987A1 (en) * 1998-11-17 2000-05-25 Smithkline Beecham Corporation Methods of treating thrombocytopenia

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
ES2116291T3 (es) 1989-10-23 1998-07-16 Nycomed Salutar Inc Agentes quelantes de metales en sitios multiples.
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
FR2672051B1 (fr) 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP0670735B1 (en) 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
GB9502022D0 (en) * 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd 末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
EP2308996A1 (en) * 1998-03-30 2011-04-13 NorthWest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 and SDF-1 genes in tumourigenesis
AU4696899A (en) * 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
CA2344653A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
EP1016413A1 (en) 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
AP1654A (en) 1999-03-24 2006-09-01 Anormed Inc Chemokine receptor binding heterocyclic compounds.
WO2000066112A1 (en) * 1999-05-03 2000-11-09 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
WO2001044229A1 (en) * 1999-12-17 2001-06-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
CA2412436C (en) * 2000-06-05 2013-05-21 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
DK1317451T3 (da) 2000-09-15 2006-12-18 Anormed Inc Kemokinreceptorbindende heterocykliske forbindelser
MXPA03002325A (es) 2000-09-15 2003-06-24 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina.
US6864265B2 (en) 2000-09-15 2005-03-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
MXPA03002772A (es) 2000-09-29 2003-07-28 Anormed Inc Procedimiento para la preparacion de poliaminas ciclicas que contienen nitrogeno en el anillo n-1 protegidos y productos de los mismos.
MXPA03006542A (es) 2001-01-23 2003-09-22 P & G Clairol Inc Intermediarios primarios para la coloracion oxidativa del cabello.
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
JP5137288B2 (ja) 2001-07-31 2013-02-06 アノーメッド インコーポレイティド 前駆／幹細胞を動員する方法
CN1596255A (zh) 2001-12-21 2005-03-16 阿诺麦德股份有限公司 具有强效的与趋化因子受体结合的杂环化合物
DE102014206089B4 (de) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000028987A1 (en) * 1998-11-17 2000-05-25 Smithkline Beecham Corporation Methods of treating thrombocytopenia

Also Published As

Publication number Publication date
NL301031I1 (nl) 2020-02-05
JP2004538303A (ja) 2004-12-24
US20150246019A1 (en) 2015-09-03
CY1112633T1 (el) 2015-08-05
NO344632B1 (no) 2020-02-17
PT1411918E (pt) 2012-03-06
HK1063005A1 (en) 2004-12-10
US20110129448A1 (en) 2011-06-02
DK2371361T3 (da) 2019-08-19
EP3632425A1 (en) 2020-04-08
PT2371361T (pt) 2019-09-10
EP1411918A2 (en) 2004-04-28
KR20040020075A (ko) 2004-03-06
LTC2371361I2 (lt) 2021-09-27
LUC00139I1 (enExample) 2019-11-27
LU92033I2 (fr) 2012-08-27
ES2380009T3 (es) 2012-05-07
US20190216773A1 (en) 2019-07-18
NO336989B1 (no) 2015-12-14
CY2012017I1 (el) 2015-08-05
ZA200400658B (en) 2005-07-27
US7897590B2 (en) 2011-03-01
BR0211570A (pt) 2004-07-13
RU2004105961A (ru) 2005-03-20
LU92033I9 (enExample) 2019-01-03
SI1411918T1 (sl) 2012-04-30
MXPA04000982A (es) 2004-04-20
JP5137288B2 (ja) 2013-02-06
CN102302493A (zh) 2012-01-04
CY2019038I1 (el) 2020-05-29
US6987102B2 (en) 2006-01-17
BRPI0211570B8 (pt) 2021-05-25
NL300537I2 (enExample) 2017-02-02
CN1561208A (zh) 2005-01-05
NZ530169A (en) 2007-04-27
WO2003011277A2 (en) 2003-02-13
FR19C1058I2 (fr) 2020-10-23
IL159312A0 (en) 2004-06-01
CA2455559A1 (en) 2003-02-13
AU2002318927B2 (en) 2007-01-04
KR20090130152A (ko) 2009-12-17
LT2371361T (lt) 2019-09-10
US20170049747A1 (en) 2017-02-23
HUP0402360A2 (hu) 2005-02-28
CY2012017I2 (el) 2015-08-05
IL159312A (en) 2015-05-31
LUC00139I2 (enExample) 2021-02-10
ATE538785T1 (de) 2012-01-15
EP2371361A1 (en) 2011-10-05
US20130273009A1 (en) 2013-10-17
FR19C1058I1 (enExample) 2019-11-22
JP2008195730A (ja) 2008-08-28
NO2016011I1 (no) 2016-06-10
CY1122199T1 (el) 2020-05-29
US20060193826A1 (en) 2006-08-31
US20080063624A1 (en) 2008-03-13
RU2309741C2 (ru) 2007-11-10
NL301031I2 (nl) 2020-07-20
CA2455559C (en) 2012-01-10
SI2371361T1 (sl) 2019-10-30
US20030130250A1 (en) 2003-07-10
US20060223180A1 (en) 2006-10-05
NO2020003I1 (no) 2020-03-05
EP1411918A4 (en) 2007-11-14
BE2019C544I2 (enExample) 2021-07-19
NO20150674A1 (no) 2015-05-27
CN102302493B (zh) 2015-08-12
CN1561208B (zh) 2010-11-10
EP2371361B1 (en) 2019-08-07
FR12C0042I1 (fr) 2012-08-10
WO2003011277A3 (en) 2003-05-22
DK1411918T3 (da) 2012-04-23
LTPA2019018I1 (lt) 2019-12-10
US7935692B2 (en) 2011-05-03
PL364673A1 (en) 2004-12-13
BRPI0211570B1 (pt) 2020-01-28
CY2019038I2 (el) 2020-05-29
NO20040407L (no) 2004-03-19
EP1411918B1 (en) 2011-12-28
ES2742730T3 (es) 2020-02-17

Similar Documents

Publication Publication Date Title
US7897590B2 (en) Methods to mobilize progenitor/stem cells
AU2002318927A1 (en) Methods to mobilize progenitor/stem cells
US20050043367A1 (en) Methods to mobilize progenitor/stem cells
JP2010507567A (ja) 併用療法
JP2009545620A (ja) 併用療法
JP2008509928A (ja) 前駆／幹細胞を動員するためのケモカインの組み合わせ
US20130095076A1 (en) Methods For Increasing Blood Flow And/Or Promoting Tissue Regeneration
HK40026817A (en) Methods to mobilize progenitor/stem cells

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20091126

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20091224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100324

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20100817

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20101118

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20101119

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20131017

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20131017

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20141021

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20141021

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20151016

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20151016

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20161019

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20161019

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20171018

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20171018

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20181018

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20181018

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20191016

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20191016

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20201015

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20211015

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20230130

Termination category: Expiration of duration